A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

NCT01171651 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: JX-594 followed by sorafenib

Sponsor

Jennerex Biotherapeutics